BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Feng B, Hess J. Immune-Related Mutational Landscape and Gene Signatures: Prognostic Value and Therapeutic Impact for Head and Neck Cancer. Cancers (Basel) 2021;13:1162. [PMID: 33800421 DOI: 10.3390/cancers13051162] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 8.0] [Reference Citation Analysis]
Number Citing Articles
1 Huehn M, Gaebel J, Oeser A, Dietz A, Neumuth T, Wichmann G, Stoehr M. Bayesian Networks to Support Decision-Making for Immune-Checkpoint Blockade in Recurrent/Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC). Cancers (Basel) 2021;13:5890. [PMID: 34884998 DOI: 10.3390/cancers13235890] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Peng YP, Wang R, Liu QD, Xu XW, Wei W, Huang XT, Peng XM, Liu ZG. Combination of Tumor Mutational Burden and Specific Gene Mutations Stratifies Outcome to Immunotherapy Across Recurrent and Metastatic Head and Neck Squamous Cell Carcinoma. Front Genet 2021;12:756506. [PMID: 34868231 DOI: 10.3389/fgene.2021.756506] [Reference Citation Analysis]
3 Dorado G, Gálvez S, Rosales TE, Vásquez VF, Hernández P. Analyzing Modern Biomolecules: The Revolution of Nucleic-Acid Sequencing - Review. Biomolecules 2021;11:1111. [PMID: 34439777 DOI: 10.3390/biom11081111] [Reference Citation Analysis]
4 Locati LD, Serafini MS, Carenzo A, Canevari S, Perrone F, Orlandi E, Delbue S, Cavalieri S, Berzeri G, Pichiecchio A, Licitra LF, Marchioni E, De Cecco L. Complete Response to Nivolumab in Recurrent/Metastatic HPV-Positive Head and Neck Squamous Cell Carcinoma Patient After Progressive Multifocal Leukoencephalopathy: A Case Report. Front Oncol 2021;11:799453. [PMID: 35083153 DOI: 10.3389/fonc.2021.799453] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Guo Y, Pan WK, Wang ZW, Su WH, Xu K, Jia H, Chen J. Identification of Novel Biomarkers for Predicting Prognosis and Immunotherapy Response in Head and Neck Squamous Cell Carcinoma Based on ceRNA Network and Immune Infiltration Analysis. Biomed Res Int 2021;2021:4532438. [PMID: 34917682 DOI: 10.1155/2021/4532438] [Reference Citation Analysis]
6 Feng B, Wang K, Herpel E, Plath M, Weichert W, Freier K, Zaoui K, Hess J. Prognostic Gene Signature for Squamous Cell Carcinoma with a Higher Risk for Treatment Failure and Accelerated MEK-ERK Pathway Activity. Cancers (Basel) 2021;13:5182. [PMID: 34680330 DOI: 10.3390/cancers13205182] [Reference Citation Analysis]
7 Fuereder T, Minichsdorfer C, Mittlboeck M, Wagner C, Heller G, Putz EM, Oberndorfer F, Müllauer L, Aretin MB, Czerny C, Schwarz-Nemec U. Pembrolizumab plus docetaxel for the treatment of recurrent/metastatic head and neck cancer: A prospective phase I/II study. Oral Oncol 2022;124:105634. [PMID: 34844042 DOI: 10.1016/j.oraloncology.2021.105634] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]